Abstract
A pilot project in New Mexico shows that pharmacists in community practice settings can effectively manage short-course regimens for the treatment of latent tuberculosis infection (LTBI). Thirty of 40 patients who started a weekly course of isoniazid and rifapentine therapy under the supervision of a pharmacist completed the full 12-week treatment, according to a report in the February 2020 issue of Preventing Chronic Disease.1 The completion rate was similar to historic rates reported for LTBI patients treated at New Mexico Department of Health offices, according to the report. Lead author Bernadette Jakeman, associate professor at the University of New Mexico (UNM) College of Pharmacy in Albuquerque, said pharmacists in the state have a long tradition of involvement in tuberculosis elimination efforts. New Mexico pharmacists have been authorized since 2011 to prescribe, administer, and read tuberculin skin tests. Jakeman and her UNM colleagues have worked with health department officials to develop pharmacy-based testing programs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
